Comparison of Residual Cancer Burden, American Joint Committee on Cancer staging and Pathologic Complete Response in Breast Cancer after Neoadjuvant Chemotherapy: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
- Citation:
- Breast Cancer Res Treat vol 165 (1) 181-191
- Year:
- 2017
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 6
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821 , U01 CA111234, U01 CA080098, U10 CA031946, U10 CA033601, U10 CA180821, U10 CA077597, U10 CA079778, P50 CA058207, U10 CA041287, U01 CA079778, U10 CA047559, U10 CA077651, P01 CA210961, U10 CA080098, U10 CA180838
- Corr. Author:
- Authors:
- Jeffrey I. Campbell Christina Yau Polina Krass Dan Moore Lisa A. Carey Alfred Au David Chhieng Dilip Giri Chad Livasy Carolyn Mies Joseph Rabban Venetia R. Sarode Baljit Singh Laura Esserman Yunn-Yi Chen
- Networks:
- Study
- CALGB-150007
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- N/A
- Keywords:
- Breast neoplasm, neoadjuvant therapy, local neoplasm recurrence, residual neoplasm, cancer staging, lymph nodes, disease-free survival, lymph nodes, Residual Cancer Burden, pathologic complete response